@article{adf2d68207284c379b2dc14bd4b9aaa9,
title = "Venetoclax in Lymphoid Malignancies: New Insights, More to Learn",
abstract = "In this issue of Cancer Cell, Gui{\`e}za et al. describe that overexpression of the pro-survival protein MCL1 and cellular energy metabolic reprogramming can contribute to resistance to the BCL2 inhibitor venetoclax in patients with chronic lymphocytic leukemia. This adds a new dimension to understanding of secondary clinical resistance to venetoclax.",
author = "Rachel Thijssen and Roberts, {Andrew W.}",
note = "Funding Information: R.T. is supported by a Fellowship for the Leukemia and Lymphoma Society (5467-18), and A.W.R is supported by a Practitioner Fellowship of the National Health and Medical Research Council of Australia ( 1079560 ). Funding Information: R.T. and A.W.R. are employees of the Walter and Eliza Hall Institute (WEHI), which receives milestone and royalty payments related to venetoclax. A.W.R. receives payments from WEHI related to venetoclax and has previously received research funding from AbbVie and Janssen. Publisher Copyright: {\textcopyright} 2019 Elsevier Inc.",
year = "2019",
month = oct,
day = "14",
doi = "https://doi.org/10.1016/j.ccell.2019.09.008",
language = "English",
volume = "36",
pages = "341--343",
journal = "Cancer cell",
issn = "1535-6108",
publisher = "Cell Press",
number = "4",
}